Global Oncology Companion Diagnostic Market Size, Status and Forecast 2024-2034
Global Oncology Companion Diagnostic Scope and Market Size
Oncology Companion Diagnostic market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Oncology Companion Diagnostic market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Immunohistochemistry (IHC)
In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
Others
Segment by Application
Hospital
Pathology/Diagnostic Laboratory
Academic Medical Center
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Agilent Technologies, Inc.
Illumina, Inc.
Qiagen N.V.
Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd.
ARUP Laboratories
Abbott
Myriad Genetics, Inc.
bioMérieux SA
Invivoscribe, Inc.

Table of Content
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oncology Companion Diagnostic Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Polymerase Chain Reaction (PCR)
1.2.3 Next-Generation Sequencing (NGS)
1.2.4 Immunohistochemistry (IHC)
1.2.5 In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
1.2.6 Others
1.3 Market by Application
1.3.1 Global Oncology Companion Diagnostic Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Pathology/Diagnostic Laboratory
1.3.4 Academic Medical Center
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Oncology Companion Diagnostic Market Perspective (2016-2027)
2.2 Oncology Companion Diagnostic Growth Trends by Regions
2.2.1 Oncology Companion Diagnostic Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Oncology Companion Diagnostic Historic Market Share by Regions (2016-2021)
2.2.3 Oncology Companion Diagnostic Forecasted Market Size by Regions (2022-2027)
2.3 Oncology Companion Diagnostic Industry Dynamic
2.3.1 Oncology Companion Diagnostic Market Trends
2.3.2 Oncology Companion Diagnostic Market Drivers
2.3.3 Oncology Companion Diagnostic Market Challenges
2.3.4 Oncology Companion Diagnostic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oncology Companion Diagnostic Players by Revenue
3.1.1 Global Top Oncology Companion Diagnostic Players by Revenue (2016-2021)
3.1.2 Global Oncology Companion Diagnostic Revenue Market Share by Players (2016-2021)
3.2 Global Oncology Companion Diagnostic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Oncology Companion Diagnostic Revenue
3.4 Global Oncology Companion Diagnostic Market Concentration Ratio
3.4.1 Global Oncology Companion Diagnostic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oncology Companion Diagnostic Revenue in 2020
3.5 Oncology Companion Diagnostic Key Players Head office and Area Served
3.6 Key Players Oncology Companion Diagnostic Product Solution and Service
3.7 Date of Enter into Oncology Companion Diagnostic Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Oncology Companion Diagnostic Breakdown Data by Type
4.1 Global Oncology Companion Diagnostic Historic Market Size by Type (2016-2021)
4.2 Global Oncology Companion Diagnostic Forecasted Market Size by Type (2022-2027)
5 Oncology Companion Diagnostic Breakdown Data by Application
5.1 Global Oncology Companion Diagnostic Historic Market Size by Application (2016-2021)
5.2 Global Oncology Companion Diagnostic Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Oncology Companion Diagnostic Market Size (2016-2027)
6.2 North America Oncology Companion Diagnostic Market Size by Type
6.2.1 North America Oncology Companion Diagnostic Market Size by Type (2016-2021)
6.2.2 North America Oncology Companion Diagnostic Market Size by Type (2022-2027)
6.2.3 North America Oncology Companion Diagnostic Market Size by Type (2016-2027)
6.3 North America Oncology Companion Diagnostic Market Size by Application
6.3.1 North America Oncology Companion Diagnostic Market Size by Application (2016-2021)
6.3.2 North America Oncology Companion Diagnostic Market Size by Application (2022-2027)
6.3.3 North America Oncology Companion Diagnostic Market Size by Application (2016-2027)
6.4 North America Oncology Companion Diagnostic Market Size by Country
6.4.1 North America Oncology Companion Diagnostic Market Size by Country (2016-2021)
6.4.2 North America Oncology Companion Diagnostic Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Oncology Companion Diagnostic Market Size (2016-2027)
7.2 Europe Oncology Companion Diagnostic Market Size by Type
7.2.1 Europe Oncology Companion Diagnostic Market Size by Type (2016-2021)
7.2.2 Europe Oncology Companion Diagnostic Market Size by Type (2022-2027)
7.2.3 Europe Oncology Companion Diagnostic Market Size by Type (2016-2027)
7.3 Europe Oncology Companion Diagnostic Market Size by Application
7.3.1 Europe Oncology Companion Diagnostic Market Size by Application (2016-2021)
7.3.2 Europe Oncology Companion Diagnostic Market Size by Application (2022-2027)
7.3.3 Europe Oncology Companion Diagnostic Market Size by Application (2016-2027)
7.4 Europe Oncology Companion Diagnostic Market Size by Country
7.4.1 Europe Oncology Companion Diagnostic Market Size by Country (2016-2021)
7.4.2 Europe Oncology Companion Diagnostic Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Oncology Companion Diagnostic Market Size (2016-2027)
8.2 Asia-Pacific Oncology Companion Diagnostic Market Size by Type
8.2.1 Asia-Pacific Oncology Companion Diagnostic Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Oncology Companion Diagnostic Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Oncology Companion Diagnostic Market Size by Type (2016-2027)
8.3 Asia-Pacific Oncology Companion Diagnostic Market Size by Application
8.3.1 Asia-Pacific Oncology Companion Diagnostic Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Oncology Companion Diagnostic Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Oncology Companion Diagnostic Market Size by Application (2016-2027)
8.4 Asia-Pacific Oncology Companion Diagnostic Market Size by Region
8.4.1 Asia-Pacific Oncology Companion Diagnostic Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Oncology Companion Diagnostic Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Oncology Companion Diagnostic Market Size (2016-2027)
9.2 Latin America Oncology Companion Diagnostic Market Size by Type
9.2.1 Latin America Oncology Companion Diagnostic Market Size by Type (2016-2021)
9.2.2 Latin America Oncology Companion Diagnostic Market Size by Type (2022-2027)
9.2.3 Latin America Oncology Companion Diagnostic Market Size by Type (2016-2027)
9.3 Latin America Oncology Companion Diagnostic Market Size by Application
9.3.1 Latin America Oncology Companion Diagnostic Market Size by Application (2016-2021)
9.3.2 Latin America Oncology Companion Diagnostic Market Size by Application (2022-2027)
9.3.3 Latin America Oncology Companion Diagnostic Market Size by Application (2016-2027)
9.4 Latin America Oncology Companion Diagnostic Market Size by Country
9.4.1 Latin America Oncology Companion Diagnostic Market Size by Country (2016-2021)
9.4.2 Latin America Oncology Companion Diagnostic Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oncology Companion Diagnostic Market Size (2016-2027)
10.2 Middle East & Africa Oncology Companion Diagnostic Market Size by Type
10.2.1 Middle East & Africa Oncology Companion Diagnostic Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Oncology Companion Diagnostic Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Oncology Companion Diagnostic Market Size by Type (2016-2027)
10.3 Middle East & Africa Oncology Companion Diagnostic Market Size by Application
10.3.1 Middle East & Africa Oncology Companion Diagnostic Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Oncology Companion Diagnostic Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Oncology Companion Diagnostic Market Size by Application (2016-2027)
10.4 Middle East & Africa Oncology Companion Diagnostic Market Size by Country
10.4.1 Middle East & Africa Oncology Companion Diagnostic Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Oncology Companion Diagnostic Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Agilent Technologies, Inc.
11.1.1 Agilent Technologies, Inc. Company Details
11.1.2 Agilent Technologies, Inc. Business Overview
11.1.3 Agilent Technologies, Inc. Oncology Companion Diagnostic Introduction
11.1.4 Agilent Technologies, Inc. Revenue in Oncology Companion Diagnostic Business (2016-2021)
11.1.5 Agilent Technologies, Inc. Recent Development
11.2 Illumina, Inc.
11.2.1 Illumina, Inc. Company Details
11.2.2 Illumina, Inc. Business Overview
11.2.3 Illumina, Inc. Oncology Companion Diagnostic Introduction
11.2.4 Illumina, Inc. Revenue in Oncology Companion Diagnostic Business (2016-2021)
11.2.5 Illumina, Inc. Recent Development
11.3 Qiagen N.V.
11.3.1 Qiagen N.V. Company Details
11.3.2 Qiagen N.V. Business Overview
11.3.3 Qiagen N.V. Oncology Companion Diagnostic Introduction
11.3.4 Qiagen N.V. Revenue in Oncology Companion Diagnostic Business (2016-2021)
11.3.5 Qiagen N.V. Recent Development
11.4 Thermo Fisher Scientific Inc.
11.4.1 Thermo Fisher Scientific Inc. Company Details
11.4.2 Thermo Fisher Scientific Inc. Business Overview
11.4.3 Thermo Fisher Scientific Inc. Oncology Companion Diagnostic Introduction
11.4.4 Thermo Fisher Scientific Inc. Revenue in Oncology Companion Diagnostic Business (2016-2021)
11.4.5 Thermo Fisher Scientific Inc. Recent Development
11.5 F. Hoffmann-La Roche Ltd.
11.5.1 F. Hoffmann-La Roche Ltd. Company Details
11.5.2 F. Hoffmann-La Roche Ltd. Business Overview
11.5.3 F. Hoffmann-La Roche Ltd. Oncology Companion Diagnostic Introduction
11.5.4 F. Hoffmann-La Roche Ltd. Revenue in Oncology Companion Diagnostic Business (2016-2021)
11.5.5 F. Hoffmann-La Roche Ltd. Recent Development
11.6 ARUP Laboratories
11.6.1 ARUP Laboratories Company Details
11.6.2 ARUP Laboratories Business Overview
11.6.3 ARUP Laboratories Oncology Companion Diagnostic Introduction
11.6.4 ARUP Laboratories Revenue in Oncology Companion Diagnostic Business (2016-2021)
11.6.5 ARUP Laboratories Recent Development
11.7 Abbott
11.7.1 Abbott Company Details
11.7.2 Abbott Business Overview
11.7.3 Abbott Oncology Companion Diagnostic Introduction
11.7.4 Abbott Revenue in Oncology Companion Diagnostic Business (2016-2021)
11.7.5 Abbott Recent Development
11.8 Myriad Genetics, Inc.
11.8.1 Myriad Genetics, Inc. Company Details
11.8.2 Myriad Genetics, Inc. Business Overview
11.8.3 Myriad Genetics, Inc. Oncology Companion Diagnostic Introduction
11.8.4 Myriad Genetics, Inc. Revenue in Oncology Companion Diagnostic Business (2016-2021)
11.8.5 Myriad Genetics, Inc. Recent Development
11.9 bioMérieux SA
11.9.1 bioMérieux SA Company Details
11.9.2 bioMérieux SA Business Overview
11.9.3 bioMérieux SA Oncology Companion Diagnostic Introduction
11.9.4 bioMérieux SA Revenue in Oncology Companion Diagnostic Business (2016-2021)
11.9.5 bioMérieux SA Recent Development
11.10 Invivoscribe, Inc.
11.10.1 Invivoscribe, Inc. Company Details
11.10.2 Invivoscribe, Inc. Business Overview
11.10.3 Invivoscribe, Inc. Oncology Companion Diagnostic Introduction
11.10.4 Invivoscribe, Inc. Revenue in Oncology Companion Diagnostic Business (2016-2021)
11.10.5 Invivoscribe, Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details